Fig. 4: Tally of the significantly replicated associations of drug sensitivity or resistance with mutation signatures and other markers.
From: Mutational signatures are markers of drug sensitivity of cancer cells
a Comparison of the number of statistically significant associations (FDR<15% by randomization test, additionally requiring an effect size d > 0.5 for GDSC/PRISM and GDSC/PSCORE tests, and d > 1 for the GDSC/GDSC (same-target) test) per feature, among mutational signatures (“Signatures”), oncogenic mutations (“Muts”) and copy number alterations (“CNAs”) in the three types of replication tests (see Fig. 3a). Features are ranked by the total number of significant associations, either for drug sensitivity (negative side of X-axis) or resistance (positive side of X-axis). b The number of different mutational signatures that have statistically significant associations across various cancer types (at FDR<15%; we consider signatures that have >1 significant association per cancer type), in the three replication tests. Source data are provided as a Source Data file.
